Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables

Journal of Clinical Oncology

Volumn 19, Issue 2, 2001, Pages 329-335

  Menard S ^a   Valagussa, P ^a   Pilotti, S ^a   Gianni, L ^a   Biganzoli, E ^a   Boracchi, P ^a   Tomasic, G ^a   Casalini, P ^a   Marubini, E ^a   Colnaghi, M I ^a   Cascinelli, N ^a   Bonadonna, G ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TAMOXIFEN;

ADULT; AGED; ARTICLE; BAYES THEOREM; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTECTOMY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0035863383     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.2.329     Document Type: Article

References (23)

1. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
2. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
3. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
4. HER2 overexpression and paclitaxel sensitivity in breast cancer: Therapeutic implications
5. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
6. c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases
7. Lack of interaction of tamoxifen (T) use and ErbB-2/HER-2/Neu (H) expression in CALGB 8541: A randomized adjuvant trial of three different doses of cyclophosphamide, doxorubicin and fluorouracil (CAF) in node-positive primary breast cancer (BC)
8. Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil
9. Prognostic importance of c-erbB-2 expression in breast cancer
10. HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma
11. Prognostic factors and response to therapy in breast cancer
12. Topoisomerase IIa deletion as well as amplification associated with erbB2 amplification in breast cancer
13. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression: DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: Prognostic implications
14. Combination chemotherapy as an adjuvant treatment in operable breast cancer
15. Pathological prognostic factors in breast cancer: I. The value of histological grade in breast cancer - Experience from a large study with long-term follow-up
16. Characterization of two monoclonal antibodies directed against the 67kDa high affinity laminin receptor and application for the study of breast carcinoma progression
17. Monoclonal antibodies against recombinant parts of the Ki- 67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections
18. Measures of association for nominal data
19. A stratified product limit estimator for the follow-up study in cardio-thoracic surgery
20. A Bayesian model for evaluating specificity of treatment effects in clinical trials
21. Proportional hazards tests and diagnostics based on weighted residuals
22. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up
23. erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer